Imbruvica (ibrutinib) capsules, 140mg (YJ code: 4291043M1027, standard: 140mg 1 capsule), manufactured by Janssen Pharmaceutical, are an anticancer medicine indicated for treating certain blood cancers like mantle cell lymphoma, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and Waldenström’s macroglobulinemia. It functions as a Bruton’s tyrosine kinase (BTK) inhibitor, blocking a protein essential for cancer cell growth and survival.
Imbruvica capsules 140mg
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →